Peptic-ulcer disease.
The discovery of Helicobacter pylori has greatly changed our approach to peptic ulcer disease. Bacterial, host, and environmental factors all have a role in peptic-ulcer disease. Although the prevalence of uncomplicated peptic ulcers is falling, hospital admissions for ulcer complications associated...
| Publicado en: | Lancet Vol. 360; no. 9337; pp. 933 - 942 |
|---|---|
| Autores principales: | , , , |
| Formato: | review tables/charts Journal Article |
| Publicado: |
Lancet
9/21/2002
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=106800003&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 106800003 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 01406736 LAN jtl: Lancet issn: 01406736 maglogo: N pubinfo: dt: 9/21/2002 vid: 360 iid: 9337 pid: 1297 pub: Lancet place: Philadelphia, Pennsylvania artinfo: ui: 106800003 106800003 NLM12354485 2003020380 10.1016/s0140-6736(02)11030-0 NLM12354485 106800003 ppf: 933 ppct: 9 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Peptic-ulcer disease. aug: au: Chan FKL Leung WK Chan, Francis K L Leung, W K affil: Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China sug: subj: Helicobacter Infections Complications Peptic Ulcer Antiinflammatory Agents, Non-Steroidal Adverse Effects Antiulcer Agents Therapeutic Use Clinical Trials Helicobacter Infections Drug Therapy Helicobacter Infections Physiopathology Peptic Ulcer Drug Therapy Peptic Ulcer Microbiology Peptic Ulcer Physiopathology Peptic Ulcer Prevention and Control ab: The discovery of Helicobacter pylori has greatly changed our approach to peptic ulcer disease. Bacterial, host, and environmental factors all have a role in peptic-ulcer disease. Although the prevalence of uncomplicated peptic ulcers is falling, hospital admissions for ulcer complications associated with non-steroidal anti-inflammatory drugs (NSAIDs) are rising. Evidence suggests that prescription of NSAIDs along with potent antiulcer agents and the use of highly selective cyclo-oxygenase-2 inhibitors reduce gastroduodenal ulceration. Whether these therapeutic advances will translate into clinical benefits remains to be seen. The interaction between H pylori and NSAIDs is one of the most controversial issues in peptic ulcer disease. With the fall in rates of H pylori infection, the proportion of ulcers not related to this organism and NSAIDs has risen, which will affect the management of peptic ulcer. pubtype: Academic Journal doctype: review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|